ino-3107
ino-3107: developed by 1 company · 1 clinical trial tracked.
ino-3107 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ino-3107 to INO; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ino-3107 → INO affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Respiratory Papillomatosis
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) Respiratory Papillomatosis | Phase 1/Phase 2 |
Clinical Trials (1)
An Open-label Multi-center Study of INO-3107 With Electroporation (EP) in Subjects With HPV-6- and/or HPV-11-associated Recurrent Respiratory Papillomatosis (RRP)
Primary endpoint: Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
Interventionalopen32 enrolledStarted 2020-10Completion 2022-1211 sites · United StatesInovio Pharmaceuticals
Frequently asked questions
Who is developing ino-3107?
ino-3107 is being developed by INOVIO PHARMACEUTICALS, INC..
How many clinical trials involve ino-3107?
BioSniper tracks 1 clinical trial involving ino-3107.